No Data
Olin Biotech (688319.SH): received a government subsidy of 2.77 million yuan.
Gelonghui January 22丨Olin Bio (688319.SH) announced that its holding subsidiary Chengdu Xinnuo Ming Biotechnology Co., Ltd. received a total of 2,773,902.60 yuan in government subsidies on January 22, 2025, of which 2,773,902.60 yuan is related to earnings and 0 yuan is related to Assets.
Individual Investors Among Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) Largest Stockholders and Were Hit After Last Week's 8.3% Price Drop
Olin Biotech (688319.SH): received a government subsidy of 2.24 million yuan.
Glonghui November 28丨 Olin Bioscience (688319.SH) announced that its wholly-owned subsidiary Chongqing Yuanlun Biological Technology Co., Ltd. recently received government subsidies totaling 2.24 million yuan, with 2.24 million yuan related to income and 0 yuan related to assets.
Chengdu Olin Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Gelonghui Announcement Highlights: PetroChina: Net income in the third quarter was 43.911 billion yuan, a decrease of 5.3% year-on-year; Muyuan Foods: Net income in the first three quarters was 10.481 billion yuan, an increase of 668.90% year-on-year.
【Performance Report】Petrochina (601857.SH): The net income in the third quarter was 43.911 billion yuan, a decrease of 5.3% year-on-year. CNSIG Inner Mongolia Chemical Industry (600328.SH): The net income in the first three quarters was 0.574 billion yuan, a decrease of 31.72% year-on-year. Datang International Power Generation (601991.SH): The net income in the first three quarters was 4.429 billion yuan, an increase of 56.22% year-on-year. Hisense Visual Technology (600060.SH): The net income in the first three quarters was 1.31 billion yuan, a decrease of 19.53% year-on-year. Yunnan Baiyao Group (000538.SZ): The net income in the first three quarters was 4.327 billion yuan, an increase.
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
Great Wisdom News on October 29th: Olin Biology (688319.SH) announced that the total amount of funds raised by the company in this stock issuance shall not exceed 175.2929 million yuan (including this amount), not exceeding 0.3 billion yuan and not exceeding 20% of the net assets at the end of the latest year. The net proceeds of the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: Vaccine research and production base technology renovation project.
Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?
